Romiplostim for the treatment of chronic immune thrombocytopenia

  • Technology appraisal guidance
  • TA221
  • Published: 
  • Last updated: 
Download guidance (PDF)

Appendix B: Sources of evidence considered by the Committee

A. The Evidence Review Group (ERG) report for this appraisal was prepared by the Aberdeen Health Technology Assessment Group:

  • Mowatt G, Boachie C, Crowther M et al., Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura (ITP): a single technology appraisal, December 2008

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to give their expert views. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I) Manufacturer/sponsor

  • Amgen

II) Professional/specialist and patient/carer groups

  • British Committee for Standards in Haematology

  • British Society for Haematology

  • ITP Support Association

  • Royal College of Nursing

  • Royal College of Pathologists

  • Royal College of Physicians

III) Other consultees

  • Department of Health

  • Eastern and Coastal Kent Teaching Primary Care Trust

  • Welsh Assembly Government

IV) Commentator organisations (did not provide written evidence and without the right of appeal)

  • Actavis UK

  • Baxter BioScience

  • Bio Products Laboratory

  • CSL Behring

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Focus Pharmaceuticals

  • GlaxoSmithKline UK

  • NHS Quality Improvement Scotland

  • Pharmacia

C. The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer/sponsor consultees and commentators. They gave their expert personal view on romiplostim for the treatment of chronic immune thrombocytopenia by attending the initial Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Dr Paula Bolton-Maggs, Consultant Haematologist, Manchester Royal Infirmary, nominated by the Royal College of Pathologists and the British Committee for Standards in Haematology – clinical specialist

  • Dr Nichola Cooper, Consultant Haematologist, Hammersmith Hospital, nominated by the ITP Support Association – clinical specialist

  • Dr John Grainger, Consultant Paediatric Haematologist, Royal Manchester Children's Hospital, nominated by the ITP Support Association – clinical specialist

  • Dr Jennie Wimperis, Consultant Haematologist, Norfolk and Norwich University Hospital, nominated by the ITP Support Association – clinical specialist

  • Mrs Shirley Watson, Chief Executive, ITP Support Association, nominated by the ITP Support Association – patient expert

  • Mr Derek Elston, nominated by the ITP Support Association – patient expert

D. Representatives from the following manufacturer/sponsor attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Amgen